Select Page

Navidea Biopharma (NAVB) Enrolls First Pediatric Patient in Lymphoseek Study

January 6, 2016 | StreetInsider | See Original Here

[COMMENT: Offered as information regarding a new Rhabdomyosarcoma clinical trial, not as information on the company or on its stock. (Alan)]

Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) announced that the first pediatric patient was enrolled in a clinical study comparing Lymphoseek® (technetium Tc 99m tilmanocept) injection and vital blue dye (VBD) in a pediatric population of patients with melanoma, rhabdomyosarcoma, or other solid tumors. The study is designed to investigate how Lymphoseek compares with VBD in identifying lymph nodes as well as evaluate safety and tolerability in the pediatric population. Lymphoseek is designed for the precise identification of lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer and is approved for adult use only. Enrollment is currently planned at approximately six sites throughout the U.S. The first patient has been enrolled by the Nationwide Children’s Hospital in Columbus, OH.

“We are pleased to participate in this important clinical study of Lymphoseek in the pediatric patient population where no lymph node mapping agents have yet been approved,” said Jennifer Aldrink, M.D., Assistant Professor of Clinical Surgery, The Ohio State University College of Medicine and Director of Surgical Oncology, Division of Pediatric Surgery at Nationwide Children’s Hospital in Columbus, OH. “Intraoperative Lymphatic Mapping (ILM) and Sentinel Lymph Node Biopsy (SLNB) are standards of care in adult and pediatric patients in several forms of cancer, and Lymphoseek is a new agent being used in many adult centers as an alternative to sulfur colloid formulation. Lymphoseek may have the potential to aid physicians in evaluating lymph nodes in children that are necessary for accurate disease staging and optimal post-surgical treatment.”

“This study will provide further data on the overall clinical value of Lymphoseek, which has already shown to be a highly effective immunodiagnostic tool in adult patients. Medical literature supports the importance of lymph node evaluations in pediatric patients with rhabdomyosarcoma and melanomas noting that lymph node metastases are highly associated with poorer survival,” said Michael Tomblyn, M.D., Chief Medical Officer of Navidea. “Until now, there have been few studies of ILM and SLNB in children. We look forward to the opportunity to evaluate Lymphoseek’s use in pediatric populations.”

This study (NAV3-18) is a prospective, open-label, multicenter study comparing Lymphoseek® and VBD as lymphoid tissue targeting agents in pediatric patients with melanoma, rhabdomyosarcoma, or other solid tumors who are undergoing lymph node mapping. Primary goals of this study are to evaluate safety and tolerability of Lymphoseek in this subject population and determine the concordance of in vivo detection rates of Lymphoseek and of VBD in tissue excised and histologically confirmed as lymph nodes. In addition, the study will measure other efficacy signals including assessment of the identified lymph node(s) to confirm: the presence/absence of tumor metastases; agent localization per tumor type; degree of localization (nodes per subject both intraoperatively and with preoperative SPECT/CT); reverse concordance parameters; change of subject stage based on histopathology and descriptive assessment on change in treatment plan; number of lymph nodes detected with Lymphoseek intraoperatively compared with preoperative SPECT/CT imaging.

Information on the protocol and enrolling sites for this study (NAV3-18) can be found at: